Risk-Based Monitoring Plan Designer for Multi-Center Phase II/III Trials
Designs a comprehensive Risk-Based Monitoring plan for a multi-center Phase II/III trial aligned to FDA and EMA RBM guidance, defining centralized statistical monitoring thresholds and on-site visit triggers.